Bio-Techne Corporation (TECH) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Minneapolis, MN, United States. Der aktuelle CEO ist Kim Kelderman.
TECH hat IPO-Datum 1989-02-09, 3,100 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $9.18B.
Bio-Techne Corporation is a life sciences company that develops, manufactures, and sells reagents, instruments, and diagnostic services for research and clinical markets globally. Operating through two main segments—Protein Sciences and Diagnostics and Genomics—the company offers a comprehensive portfolio including biological reagents, antibodies, cytokines, proteomic analytical tools, and diagnostic assays for oncology, genetic screening, and molecular diagnostics. Its products serve cell and gene therapy, tissue analysis, and hematology applications under recognized brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, and Asuragen. Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne has established itself as a trusted supplier to academic institutions, pharmaceutical companies, clinical laboratories, and diagnostic centers worldwide.
